Hong Kong stocks closed higher on September 21, with the HSI up 1.18%. BIRENTECH led AI concept stocks with a 12.23% gain, followed by BLACK SESAME at 6.30%.
On September 21, 2026, XPENG-W (09868.HK) edged lower in the afternoon. As of 15:01, it quoted HK$40.46, down 3.76%.
On 21 September, SMIC (00981.HK) quoted HKD 64.900, down 0.38%. UMC signalled price rises, PSMC up to 40%; South Korea 1-20 September chip exports rose 259%.
on 21 September 2026, humanoid robot stocks traded with volatility while UBTECH ROBOTICS (09880.HK) weakened. As of 13:10, the company quoted HKD 79.350, down 1.86%.SCS believes that humanoid robots have entered the order validation phase, with the industry's main theme shifting from single product launches to mass production validation and large-scale commercialisation.
On 21 September 2026, INSILICO (03696.HK) announced a collaboration worth up to tens of millions of US dollars with a frontier foundation model laboratory to jointly develop and commercialise biology foundation models.
On 21 September 2026, ABBISKO-B (02256.HK) announced that lavengratinib, its FGFR2/3 inhibitor, showed positive interim Phase II results in paediatric achondroplasia, with AHV rising 2.4 cm/year from baseline and a 100% response rate at 27 weeks.
On 21 September 2026, CUTIA-B (02487.HK) announced that CU-40102 (topical finasteride spray) received marketing approval in Macao for androgenetic alopecia, following earlier approvals in the Chinese mainland and Hong Kong.
On 18 September 2026, TRANSTHERA-B (02617.HK) announced that its self-developed Jeentai® (tinengotinib) has been included in the CSCO Guidelines for the Diagnosis and Treatment of Biliary Tract Malignancies as a Class II recommendation, category 2A, for advanced biliary tract malignancies.
On 18 September 2026, IMPACT THERAP-B (07630.HK) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of sepalna (Sepalna®) for the maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer, with the application to be submitted to the European Commission for a final decision.
On September 18, 2026, the three major Hong Kong indices rebounded collectively, with the Hang Seng Index up 0.60%, the Hang Seng TECH Index surging 2.20%, and the Hang Seng China Enterprises Index up 0.61%. The Hang Seng Index's full-day total market turnover was 266.5 billion HKD, Southbound funds saw a net inflow of 1.193 billion HKD.
On 18 September 2026, SHANDONG XINHUA (00719.HK) disclosed that it recently obtained the drug registration certificate for levocarnitine oral solution issued by the National Medical Products Administration.
On September 18, 2026, BIDU-W (09888.HK) traded stronger. As of 15:04, it was quoted at HK$88.80, up 1.66%.
on 18 September 2026, AI chip stocks traded strongly, with HUA HONG GRACE (01347.HK) strengthening. As of 14:00, the company quoted HKD 115.400, up 4.72%.
on 18 September 2026, humanoid robot stocks traded strongly, with EXCELLAND ROBOT (03231.HK) strengthening. As of 13:45, the company quoted HKD 38.040, up 0.58%.
On 17 September 2026, GENSCRIPT BIO (01548.HK) published an announcement under Rule 13.10 of the Listing Rules, disclosing a collaboration with Lilly TuneLab™, an AI-driven drug discovery collaboration platform founded by Lilly, under which the Group will provide wet-lab services to TuneLab participating enterprises at preferential rates.
On September 17, 2026, the three major Hong Kong indices opened lower and moved in a choppy range, with the Hang Seng Index down 0.44%, the Hang Seng TECH Index down 0.34%, and the Hang Seng China Enterprises Index down 0.38%. The full-day total market turnover was 185.6 billion HKD, higher than that of the previous trading day. Southbound funds saw a net inflow of 3.363 billion HKD.
